{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,3]],"date-time":"2025-08-03T01:10:23Z","timestamp":1754183423932,"version":"3.41.2"},"reference-count":30,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,30]]},"DOI":"10.1248\/bpb.b25-00168","type":"journal-article","created":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:08:12Z","timestamp":1753826892000},"page":"1125-1130","source":"Crossref","is-referenced-by-count":0,"title":["Bleeding Risk in the Early Postoperative Period after Atrial Fibrillation Ablation with Anticoagulant Therapy Using Dabigatran Etexilate"],"prefix":"10.1248","volume":"48","author":[{"given":"Yasuyuki","family":"Takashima","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"},{"name":"Tsukuba Clinical Research and Development Organization, University of Tsukuba, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Doki","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasutoshi","family":"Shinoda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Komatsu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miyako","family":"Igarashi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Institute of Medicine, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Homma","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba, 1\u20131\u20131 Tennodai, Tsukuba, Ibaraki 305\u20138575, Japan"},{"name":"Department of Pharmacy, University of Tsukuba Hospital, 2\u20131\u20131 Amakubo, Tsukuba, Ibaraki 305\u20138576, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L. Dabigatran <i>versus<\/i> warfarin in patients with atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>361<\/b>, 1139\u20131151 (2009).","DOI":"10.1056\/NEJMoa0905561"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet<\/i>, <b>376<\/b>, 975\u2013983 (2010).","DOI":"10.1016\/S0140-6736(10)61194-4"},{"key":"3","unstructured":"3) Pradaxa: EPAR\u2014product information. &lt;https:\/\/www.ema.europa.eu\/documents\/product-information\/pradaxa-epar-product-information_en.pdf&gt;, accessed 4 November, 2024."},{"key":"4","unstructured":"4) Prazaxa: interview form. Revised, November, 2023.: &lt;http:\/\/bij-kusuri.jp\/products\/files\/pxa_cap75_if.pdf&gt;,  accessed 21 January, 2025."},{"key":"5","unstructured":"5) Pradaxa: prescribing information. &lt;https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/022512s047lbl.pdf&gt;, Revised, November, 2023."},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Stangier J, Rathgen K, St\u00e4hle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. <i>Clin. Pharmacokinet.<\/i>, <b>49<\/b>, 259\u2013268 (2010).","DOI":"10.2165\/11318170-000000000-00000"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) H\u00e4rtter S, Sennewald R, Nehmiz G, Reilly P. Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. <i>Br. J. Clin. Pharmacol.<\/i>, <b>75<\/b>, 1053\u20131062 (2013).","DOI":"10.1111\/j.1365-2125.2012.04453.x"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H, Christ H, Vogt J, B\u00e4nsch D, iebels J, Boersma L, Jordaens L, Merkely B, Pokushalov E, Sanders P, Proff J, Schunkert H. Catheter ablation for atrial fibrillation with heart failure. <i>N. Engl. J. Med.<\/i>, <b>378<\/b>, 417\u2013427 (2018).","DOI":"10.1056\/NEJMoa1707855"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Di Biase L, Mohanty P, Mohanty S, <i>et al<\/i>. Ablation <i>versus<\/i> amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. <i>Circulation<\/i>, <b>133<\/b>, 1637\u20131644 (2016).","DOI":"10.1161\/CIRCULATIONAHA.115.019406"},{"key":"10","unstructured":"10) Packer DL, Mark DB, Robb RA, <i>et al<\/i>. Effect of catheter ablation <i>vs<\/i>. antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. <i>JAMA<\/i>, <b>321<\/b>, 1261\u20131274 (2019)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Fran\u00e7a MRQ, Morillo CA, Carmo AAL, Mayrink M, Miranda RC, Naback AD, Nevis I, Silva GA, Ribeiro AL, Nascimento BR. Efficacy and safety of catheter ablation for atrial fibrillation in elderly patients: a systematic review and meta-analysis. <i>J. Interv. Card. Electrophysiol.<\/i>, <b>67<\/b>, 1691\u20131707 (2024).","DOI":"10.1007\/s10840-024-01755-5"},{"key":"12","unstructured":"12) Hindricks G, Potpara T, Dagres N, <i>et al<\/i>. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. <i>Eur. Heart J.<\/i>, <b>42<\/b>, 373\u2013498 (2021)."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. <i>Am. Heart J.<\/i>, <b>157<\/b>, 805\u2013810.e2 (2009).","DOI":"10.1016\/j.ahj.2009.02.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. <i>Am. Heart J.<\/i>, <b>159<\/b>, 340\u2013347.e1 (2010).","DOI":"10.1016\/j.ahj.2009.11.025"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. <i>Am. Heart J.<\/i>, <b>159<\/b>, 331\u2013339 (2010).","DOI":"10.1016\/j.ahj.2009.07.035"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the effective aNticoaGulation with factor xA next GEneration in atrial fibrillation-thrombolysis in myocardial infarction study 48 (ENGAGE AF-TIMI 48). <i>Am. Heart J.<\/i>, <b>160<\/b>, 635\u2013641.e2 (2010).","DOI":"10.1016\/j.ahj.2010.06.042"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, Heidenreich PA, Murray KT, Shea JB, Tracy CM, Yancy CW. 2019 AHA\/ACC\/HRS focused update of the 2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons. <i>Circulation<\/i>, <b>140<\/b>, e125\u2013e151 (2019).","DOI":"10.1161\/CIR.0000000000000665"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R, Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer MA, Grimaldi M. Uninterrupted dabigatran <i>versus<\/i> warfarin for ablation in atrial fibrillation. <i>N. Engl. J. Med.<\/i>, <b>376<\/b>, 1627\u20131636 (2017).","DOI":"10.1056\/NEJMoa1701005"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. <i>J. Thromb. Haemost.<\/i>, <b>3<\/b>, 692\u2013694 (2005).","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Liesenfeld KH, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, Yusuf S, Wallentin L, Haertter S, Staab A. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. <i>J. Thromb. Haemost.<\/i>, <b>9<\/b>, 2168\u20132175 (2011).","DOI":"10.1111\/j.1538-7836.2011.04498.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, Ezekowitz MD, Nehmiz G, Wang S, Wallentin L. RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). <i>J. Am. Coll. Cardiol.<\/i>, <b>63<\/b>, 321\u2013328 (2014).","DOI":"10.1016\/j.jacc.2013.07.104"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Doki K, Neuhoff S, Rostami-Hodjegan A, Homma M. Assessing potential drug-drug interactions between dabigatran etexilate and a P-glycoprotein inhibitor in renal impairment populations using physiologically based pharmacokinetic modeling. <i>CPT Pharmacometrics Syst. Pharmacol.<\/i>, <b>8<\/b>, 118\u2013126 (2019).","DOI":"10.1002\/psp4.12382"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Nogami A, Harada T, Sekiguchi Y, Otani R, Yoshida Y, Yoshida K, Nakano Y, Nuruki N, Nakahara S, Goya M, Origasa H, Kihara Y, Hirao K, Aonuma K. ABRIDGE-J (ABlation peRIoperative DabiGatran in use Envisioning in Japan) Investigators. Safety and efficacy of minimally interrupted dabigatran <i>vs<\/i>. uninterrupted warfarin therapy in adults undergoing atrial fibrillation catheter ablation: a randomized clinical trial. <i>JAMA Netw. Open<\/i>, <b>2<\/b>, e191994 (2019).","DOI":"10.1001\/jamanetworkopen.2019.1994"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Nin T, Sairaku A, Yoshida Y, Kamiya H, Tatematsu Y, Nanasato M, Inden Y, Hirayama H, Murohara T. A randomized controlled trial of dabigatran <i>versus<\/i> warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. <i>Pacing Clin. Electrophysiol.<\/i>, <b>36<\/b>, 172\u2013179 (2013).","DOI":"10.1111\/pace.12036"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Nakamura K, Naito S, Sasaki T, Minami K, Take Y, Goto E, Shimizu S, Yamaguchi Y, Suzuki N, Yano T, Senga M, Kumagai K, Kaseno K, Funabashi N, Oshima S. Silent cerebral ischemic lesions after catheter ablation of atrial fibrillation in patients on 5 types of periprocedural oral anticoagulation - predictors of diffusion-weighted imaging-positive lesions and follow-up magnetic resonance imaging. <i>Circ. J.<\/i>, <b>80<\/b>, 870\u2013877 (2016).","DOI":"10.1253\/circj.CJ-15-1368"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Okishige K, Nakamura T, Aoyagi H, Kawaguchi N, Yamashita M, Kurabayashi M, Suzuki H, Asano M, Shimura T, Yamauchi Y, Sasano T, Hirao K. Comparative study of hemorrhagic and ischemic complications among anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillation. <i>J. Cardiol.<\/i>, <b>69<\/b>, 11\u201315 (2017).","DOI":"10.1016\/j.jjcc.2016.04.009"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Yamaji H, Murakami T, Hina K, Higashiya S, Kawamura H, Murakami M, Kamikawa S, Komtasubara I, Kusachi S. Adequate initial heparin dosage for atrial fibrillation ablation in patients receiving non-vitamin k antagonist oral anticoagulants. <i>Clin. Drug Investig.<\/i>, <b>36<\/b>, 837\u2013848 (2016).","DOI":"10.1007\/s40261-016-0435-6"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Kimata A, Nogami A, Yamasaki H, Ohigashi T, Gosho M, Igarashi M, Sekiguchi Y, Ieda M, Calkins H, Aonuma K. Optimal interruption time of dabigatran oral administration to ablation (O-A time) in patients with atrial fibrillation: integrated analysis of 2 randomized controlled clinical trials. <i>J. Cardiol.<\/i>, <b>77<\/b>, 652\u2013659 (2021).","DOI":"10.1016\/j.jjcc.2020.12.010"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Nakamura K, Naito S, Sasaki T, Take Y, Minami K, Kitagawa Y, Motoda H, Inoue M, Otsuka Y, Niijima K, Yamashita E, Sugai Y, Kumagai K, Koyama K, Funabashi N, Oshima S. Uninterrupted <i>vs<\/i>. interrupted periprocedural direct oral anticoagulants for catheter ablation of atrial fibrillation: a prospective randomized single-centre study on post-ablation thrombo-embolic and haemorrhagic events. <i>Europace<\/i>, <b>21<\/b>, 259\u2013267 (2019).","DOI":"10.1093\/europace\/euy148"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Nakamura R, Okishige K, Shigeta T, Nishimura T, Kurabayashi M, Yamauchi Y, Sasano T, Hirao K. Clinical comparative study regarding interrupted and uninterrupted dabigatran therapy during perioperative periods of cryoballoon ablation for paroxysmal atrial fibrillation. <i>J. Cardiol.<\/i>, <b>74<\/b>, 150\u2013155 (2019).","DOI":"10.1016\/j.jjcc.2019.02.003"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00168\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T04:04:55Z","timestamp":1754107495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00168\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00168","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"type":"print","value":"0918-6158"},{"type":"electronic","value":"1347-5215"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"article-number":"b25-00168"}}